VICARIOUS SURGICAL INC. Financials Vicarious Surgical Inc.
Equities
RBOT
US92561V1098
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2806 USD | +0.21% |
|
-1.06% | -23.48% |
| Apr. 29 | Transcript : Vicarious Surgical Inc., Q1 2024 Earnings Call, Apr 29, 2024 | |
| Apr. 29 | Vicarious Surgical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | - | 1,260 | 247.2 | 64.13 | 49.4 | - | - |
| Enterprise Value (EV) 1 | - | 1,088 | 247.2 | -19.21 | 12.8 | -21.42 | 34.16 |
| P/E ratio | -4.58 x | -177 x | 50.5 x | -0.75 x | -0.78 x | -0.66 x | -0.63 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - |
| EV / EBITDA | - | -31.8 x | -3.13 x | 0.24 x | -0.2 x | 0.33 x | -0.51 x |
| EV / FCF | - | -31,445,339 x | - | - | - | - | - |
| FCF Yield | - | -0% | - | - | - | - | - |
| Price to Book | - | 15.3 x | - | 0.66 x | 1.04 x | 0.83 x | 2.81 x |
| Nbr of stocks (in thousands) | - | 118,622 | 122,370 | 174,889 | 176,035 | - | - |
| Reference price 2 | 10.16 | 10.62 | 2.020 | 0.3667 | 0.2806 | 0.2806 | 0.2806 |
| Announcement Date | 6/11/21 | 3/3/22 | 2/13/23 | 3/4/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA 1 | - | -34.21 | -78.97 | -78.81 | -64.24 | -64.55 | -67.23 |
| EBIT 1 | - | -38.57 | -80.08 | -80.67 | -63.29 | -73.99 | -78.78 |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -7.268 | 5.157 | -71.07 | -67.3 | -79.1 | -82.9 |
| Net income 1 | -12.88 | -7.268 | 5.157 | -71.07 | -63.5 | -75.23 | -78.93 |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | -2.220 | -0.0600 | 0.0400 | -0.4900 | -0.3600 | -0.4233 | -0.4433 |
| Free Cash Flow | - | -34.59 | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 6/11/21 | 3/3/22 | 2/13/23 | 3/4/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | -8.476 | -14.99 | -18 | -18.94 | -21.82 | -20.21 | -21.87 | -21.02 | -20.9 | -15.02 | -15.95 | -16.1 | -16.8 | -16.1 | -20.05 |
| EBIT 1 | -8.561 | -18.17 | -18.18 | -19.13 | -22.16 | -20.61 | -22.32 | -21.46 | -21.35 | -15.54 | -16.11 | -15.1 | -15.45 | -15.95 | -20.1 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -65.48 | 70.08 | 42.53 | -1.453 | -24.74 | -11.18 | -26.92 | -15.33 | -15.7 | -13.11 | -17 | -16.3 | -16.7 | -17.3 | -20.6 |
| Net income 1 | -65.48 | 70.08 | 42.53 | -1.453 | -24.74 | -11.18 | -26.92 | -15.33 | -15.7 | -13.11 | -17 | -15.1 | -15.45 | -15.95 | -20.6 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.7100 | 0.5900 | 0.3300 | -0.0100 | -0.2000 | -0.0900 | -0.2100 | -0.1200 | -0.1000 | -0.0600 | -0.1000 | -0.0850 | -0.0850 | -0.0900 | -0.1200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 3/3/22 | 5/9/22 | 8/8/22 | 11/7/22 | 2/13/23 | 5/8/23 | 7/27/23 | 11/13/23 | 3/4/24 | 4/29/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 172 | - | 83.3 | 36.6 | 70.8 | 15.2 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | -34.6 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -77.3% | - | -68% | -85.5% | -107% | -147% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 0.6900 | - | 0.5600 | 0.2700 | 0.3400 | 0.1000 |
| Cash Flow per Share | - | -0.3400 | - | - | - | - | - |
| Capex | - | 1.29 | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 6/11/21 | 3/3/22 | 2/13/23 | 3/4/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.28
USD
Average target price
1.033
USD
Spread / Average Target
+269.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.48% | 49.29M | |
| +7.15% | 220B | |
| +6.60% | 183B | |
| +9.86% | 133B | |
| +24.32% | 107B | |
| -0.95% | 63.05B | |
| +11.04% | 51.74B | |
| +4.81% | 50.47B | |
| -1.43% | 40.91B | |
| +24.40% | 31.91B |
- Stock Market
- Equities
- RBOT Stock
- Financials Vicarious Surgical Inc.
